Item 7.01. Regulation FD Disclosure

On October 2, 2012, DARA BioSciences, Inc, (the "Company") reported that on October 1, 2012, NASDAQ notified the Company that it has regained compliance with Rule 5550(a)(2), which requires a minimum bid price of $1.00 for continued listing on the NASDAQ Stock Market (the "Minimum Bid Price Rule").

The Company further announced that in light of the Company's regaining compliance with the Minimum Bid Price Rule, the special meeting of stockholders that was scheduled to take place on November 8, 2012 to consider a reverse stock split proposal has been cancelled.
On October 2, 2012, the Company issued a press release, a copy of which is being furnished as Exhibit 99 to this Report on Form 8-K.

---